{"id":63863,"date":"2026-06-16T07:51:30","date_gmt":"2026-06-16T06:51:30","guid":{"rendered":"https:\/\/www.promedical.co.uk\/?p=63863"},"modified":"2026-06-16T07:51:30","modified_gmt":"2026-06-16T06:51:30","slug":"patient-safety-signals-and-medico-legal-risk-in-2026","status":"publish","type":"post","link":"https:\/\/www.promedical.co.uk\/healthcare-leadership\/patient-safety-signals-and-medico-legal-risk-in-2026\/","title":{"rendered":"Patient Safety Signals and Medico-Legal Risk in 2026"},"content":{"rendered":"

The March 2026 NHS England Board papers show a patient safety picture that is improving in some\u00a0areas, but\u00a0still carrying significant risk.<\/span>\u00a0<\/span><\/p>\n

There are positive signals. Stillbirth and neonatal death rates have reduced. Crisis care face-to-face contact within 24 hours has improved. Restrictive intervention use in mental health has reduced year on year. Some healthcare-associated infection indicators are lower than the previous year. Cancer early diagnosis has also improved on a 12-month average.\u00a0<\/span>\u00a0<\/span><\/p>\n

But the same Board pack also shows why the risk environment\u00a0remains\u00a0serious. Staff confidence in raising concerns has weakened. Around two thirds of trusts with a recent CQC safe inspection rating were rated requires improvement or inadequate. Eleven providers had higher-than-expected mortality. Diagnostic waits have worsened year on year. Cancer standards\u00a0remain\u00a0below ambition. Community long waits have risen sharply.\u00a0<\/span>\u00a0<\/span><\/p>\n

For medico-legal audiences, the key point is not that the March Board pack quantifies the clinical negligence bill. It does not. The documents do not provide NHS Resolution claims costs, compensation\u00a0provisions\u00a0or a quantified national negligence liability. It would therefore be inappropriate to make claims about the size or movement of the clinical negligence bill from these papers alone.<\/span>\u00a0<\/span><\/p>\n

The core signal is more precise:\u00a0<\/span>the Board papers\u00a0identify\u00a0the safety, delay,\u00a0culture\u00a0and variation indicators that can shape future clinical risk if they are not addressed early.<\/span><\/b>\u00a0<\/span><\/p>\n

Medico-Legal Evidence Boundary<\/h3>\n

This blog interprets medico-legal risk through published NHS England Board data. It does not infer liability,\u00a0causation\u00a0or negligence from any single metric.<\/span>\u00a0<\/span><\/p>\n

A higher-than-expected mortality indicator, a delayed diagnostic pathway or a weakened raising-concerns score does not automatically mean clinical negligence has occurred. These are risk signals. They point to areas where provider boards, clinical leaders and governance teams may need stronger assurance, better escalation, improved\u00a0documentation\u00a0and clearer learning mechanisms.<\/span>\u00a0<\/span><\/p>\n

The medico-legal relevance is therefore indirect but important. Clinical negligence risk often crystallises after harm has occurred, but the conditions that increase exposure can appear earlier: delay, poor communication, missed escalation, weak safety culture, inconsistent documentation, variation in care quality and insufficient learning from incidents.<\/span><\/p>\n

Safety culture is a leading risk signal<\/h3>\n

One of the most important patient safety indicators in the March Board pack is the NHS Staff Survey raising-concerns score.<\/span>\u00a0<\/span><\/p>\n

The Integrated Performance Report shows that the national average score for staff saying they would feel secure raising concerns about unsafe clinical practice fell to\u00a0<\/span>6.37 in 2025<\/span><\/b>, down from\u00a0<\/span>6.45 in 2024<\/span><\/b>. NHS England notes that the score has declined from\u00a0<\/span>6.54 in 2021<\/span><\/b>, signalling a gradual downward trend in confidence to raise concerns or believe that action would be taken.\u00a0<\/span>\u00a0<\/span><\/p>\n

This matters because the ability to raise concerns is one of the NHS\u2019s most important early-warning systems. When staff feel less secure about speaking up, risks may remain unresolved for longer. That can affect escalation, incident learning, clinical\u00a0governance\u00a0and patient safety assurance.<\/span>\u00a0<\/span><\/p>\n

The People Committee papers reinforce this issue. The Committee received a summary of a recent Non-Executive Director call with Freedom to Speak Up Guardians and noted that the discussion\u00a0provided\u00a0useful insight into staff concerns and organisational culture. It agreed that themes arising from those discussions should continue to inform wider workforce and cultural considerations.\u00a0<\/span>\u00a0<\/span><\/p>\n

From a medico-legal perspective, speaking-up culture is not a peripheral workforce topic. It is central to risk prevention. Many adverse events become more serious when warning signs are not escalated, when concerns are not heard, or when staff do not believe action will follow.<\/span>\u00a0<\/span><\/p>\n

The implication for provider leaders is clear: safety culture must be treated as a board-level risk control, not simply as an engagement measure.<\/span><\/p>\n

Mortality and CQC variation require careful assurance<\/h3>\n

The March Board papers also highlight significant variation in safety oversight indicators.<\/span>\u00a0<\/span><\/p>\n

The Integrated Performance Report states that\u00a0<\/span>11 providers<\/span><\/b>\u00a0had higher-than-expected mortality for the period\u00a0<\/span>1 November 2024 to 31 October 2025<\/span><\/b>. Five of those providers also had higher-than-expected deaths for the same reporting period in the previous year. The report notes\u00a0possible data\u00a0quality issues for several providers, which is an important\u00a0caveat.\u00a0<\/span>\u00a0<\/span><\/p>\n

That\u00a0caveat\u00a0matters. Summary Hospital Level Mortality Indicator data should not be read as a direct measure of avoidable deaths. It is a signal requiring review,\u00a0context\u00a0and assurance. But it\u00a0remains\u00a0important because mortality indicators can\u00a0identify\u00a0variation that\u00a0warrants\u00a0closer clinical, coding,\u00a0pathway\u00a0and governance scrutiny.<\/span>\u00a0<\/span><\/p>\n

CQC safe inspection ratings provide another signal. The March report shows that, among trusts with a safe inspection rating awarded within the preceding two years,\u00a0<\/span>34.0%<\/span><\/b>\u00a0were rated good and\u00a0<\/span>0.7%<\/span><\/b>\u00a0outstanding. By contrast,\u00a0<\/span>63.9%<\/span><\/b>\u00a0were rated requires improvement and\u00a0<\/span>1.4%<\/span><\/b>\u00a0inadequate. NHS England summarises this as around two thirds of recently inspected trusts being rated requires improvement or inadequate for safety.\u00a0<\/span>\u00a0<\/span><\/p>\n

This is one of the strongest safety governance signals in the Board pack. It shows that the NHS\u2019s patient safety challenge is not limited to isolated incidents. It includes variation in the underlying systems that support safe care.<\/span>\u00a0<\/span><\/p>\n

The report states that the NHS will implement a new Quality Strategy as part of the\u00a010 Year\u00a0Health Plan, including easier-to-understand provider league tables, stronger board accountability through the \u201cInsightful Provider Board\u201d approach, and regular engagement between national, regional and trust clinical leadership. It also references reform of the quality and patient safety landscape, including support for the CQC towards a more data-led regulatory model.\u00a0<\/span>\u00a0<\/span><\/p>\n

For medico-legal stakeholders, the direction is significant. Safety assurance is becoming more transparent, more data-led and more directly connected to provider-board accountability.<\/span><\/p>\n

Delayremainsa patient safety and legal risk theme<\/h3>\n

The most obvious medico-legal risk theme in the March Board papers is delayed care.<\/span>\u00a0<\/span><\/p>\n

The total elective waiting list fell to\u00a0<\/span>7,247,214<\/span><\/b>\u00a0in January 2026, down from December 2025 and down year on year. Long elective waits also reduced. But Referral to Treatment performance at 18 weeks was\u00a0<\/span>61.5%<\/span><\/b>, still below the 2025\/26 requirement of\u00a0<\/span>65%<\/span><\/b>.\u00a0<\/span>\u00a0<\/span><\/p>\n

Diagnostics are more pressured. In January 2026,\u00a0<\/span>24.7%<\/span><\/b>\u00a0of patients were waiting more than six weeks for a diagnostic procedure or test, worse than\u00a0<\/span>22.4%<\/span><\/b>\u00a0in January 2025. NHS England attributes this to activity growth not keeping pace with demand growth.\u00a0<\/span>\u00a0<\/span><\/p>\n

Cancer performance shows the clinical consequence of pathway pressure. The Faster Diagnosis Standard was\u00a0<\/span>72.8%<\/span><\/b>\u00a0in January 2026, down from December and slightly worse than January 2025. The 62-day combined cancer standard was\u00a0<\/span>68.4%<\/span><\/b>\u00a0against the\u00a0<\/span>80% planning guidance ambition<\/span><\/b>, although slightly improved year on year.\u00a0<\/span>\u00a0<\/span><\/p>\n

Community services add another risk layer. Patients waiting more than 52 weeks for community services increased to\u00a0<\/span>90,049<\/span><\/b>\u00a0in January 2026, up\u00a0<\/span>32.7%<\/span><\/b>\u00a0year on year. NHS England states that\u00a0<\/span>90%<\/span><\/b>\u00a0of all over-52-week community waits are in children\u2019s services, with\u00a0<\/span>82%<\/span><\/b>\u00a0in community paediatrics,\u00a0largely driven\u00a0by demand for neurodevelopmental assessment.\u00a0<\/span>\u00a0<\/span><\/p>\n

For patients, delayed care can mean prolonged symptoms, deterioration, later diagnosis, delayed treatment\u00a0decisions\u00a0and reduced confidence in the system. For healthcare workers, it can mean difficult prioritisation, more complex case\u00a0management\u00a0and greater pressure at points of escalation.<\/span>\u00a0<\/span><\/p>\n

For medico-legal teams, the key areas of exposure are likely to be delayed diagnosis, delayed treatment, avoidable deterioration, communication failures, handover\u00a0risk\u00a0and documentation gaps. The Board pack does not quantify how many incidents may lead to claims, and no such inference should be made. But it does show the pathway conditions in which risk can arise.<\/span><\/p>\n

Infection,maternityand mental health show mixed signals<\/h3>\n

The patient safety section of the Integrated Performance Report shows a mixed picture across infection control,\u00a0maternity\u00a0and mental health.<\/span>\u00a0<\/span><\/p>\n

On infection control,\u00a0<\/span>C. difficile<\/span><\/b>\u00a0healthcare-associated infections stood at\u00a0<\/span>816<\/span><\/b>\u00a0in January 2026, up from\u00a0<\/span>742<\/span><\/b>\u00a0in December 2025 but down from\u00a0<\/span>974<\/span><\/b>\u00a0in January 2025.\u00a0<\/span>E. coli<\/span><\/b>\u00a0healthcare-associated infections were\u00a0<\/span>1,153<\/span><\/b>\u00a0in January 2026, down from\u00a0<\/span>1,191<\/span><\/b>\u00a0in December 2025 and down slightly from\u00a0<\/span>1,192<\/span><\/b>\u00a0in January 2025.\u00a0<\/span>MRSA<\/span><\/b>\u00a0healthcare-associated infections were\u00a0<\/span>59<\/span><\/b>\u00a0in January 2026, up from\u00a0<\/span>24<\/span><\/b>\u00a0in December 2025 and\u00a0<\/span>40<\/span><\/b>\u00a0in January 2025, although NHS England states there is insufficient data to\u00a0determine\u00a0whether this increase is natural variation and that the level\u00a0remains\u00a0below tolerance levels.\u00a0<\/span>\u00a0<\/span><\/p>\n

The infection signal is therefore not uniform. Some indicators are lower year on year, but surveillance, antimicrobial stewardship and infection prevention remain important. From a risk perspective, infection-related harm can involve pathway, environment, antimicrobial,\u00a0escalation\u00a0and documentation issues. Continued monitoring is therefore essential.<\/span>\u00a0<\/span><\/p>\n

Maternity and neonatal safety also show mixed signals. The stillbirth rate was\u00a0<\/span>3.8 per 1,000 total births in 2024<\/span><\/b>, down from\u00a0<\/span>3.94 in 2023<\/span><\/b>. The neonatal mortality rate was\u00a0<\/span>1.4 per 1,000 live births in 2023<\/span><\/b>, down from\u00a0<\/span>1.47 in 2022<\/span><\/b>. However, the report also\u00a0states\u00a0that maternal mortality data recorded\u00a0<\/span>252 direct and indirect deaths between 2022 and 2024<\/span><\/b>, excluding six COVID-19 cases, with the rate rising to\u00a0<\/span>12.5 per 100,000 maternities<\/span><\/b>.\u00a0<\/span>\u00a0<\/span><\/p>\n

The March papers describe several actions, including the Maternity Outcomes Signal System, launched in November 2025, which uses near-real-time data to flag intrapartum safety concerns, trigger rapid reviews within eight working days and escalate issues to trust boards where\u00a0required.\u00a0<\/span>\u00a0<\/span><\/p>\n

Mental health safety shows some improvement. Restrictive intervention use was\u00a0<\/span>32 per 1,000 occupied bed days<\/span><\/b>\u00a0in January 2026, down from\u00a0<\/span>36<\/span><\/b>\u00a0in January 2025. Crisis care face-to-face contact within 24 hours improved to\u00a0<\/span>67.4%<\/span><\/b>\u00a0in January 2026, up from\u00a0<\/span>59.5%<\/span><\/b>\u00a0in January 2025. But community mental health experience\u00a0remains\u00a0weak, with\u00a0<\/span>47.7%<\/span><\/b>\u00a0of 2024 survey respondents rating their experience as good, down slightly from\u00a0<\/span>48.1%<\/span><\/b>\u00a0in 2023.\u00a0<\/span>\u00a0<\/span><\/p>\n

The overall signal is that safety improvement is possible, but fragile. Progress in one metric does not remove risk in another.<\/span><\/p>\n

Transparency is changing the risk environment<\/h3>\n

The March Board papers show that transparency is becoming a central part of safety and accountability.<\/span>\u00a0<\/span><\/p>\n

The Integrated Performance Report references provider league tables, patient-reported\u00a0experience\u00a0and outcome measures, CQC reform towards a more data-led model, and the use of quality data to support patient choice. The inpatient experience section\u00a0states\u00a0that the NHS App will be developed to allow patients to search and choose providers based on quality data, length of wait, patient\u00a0ratings\u00a0and clinical outcomes.\u00a0<\/span>\u00a0<\/span><\/p>\n

The February Board minutes also show the direction of travel. The Board supported extending transparency across non-acute services and patient experience datasets, linking information to patient choice tools, and considering publication of clinical outcome metrics by specialty.\u00a0<\/span>\u00a0<\/span><\/p>\n

For provider leaders, this changes the risk environment. Safety, quality, experience,\u00a0outcomes\u00a0and waits are becoming more visible. That visibility can support improvement, but it also increases the need for robust local assurance. Public data must be\u00a0accurate,\u00a0contextualised\u00a0and connected to real improvement activity.<\/span>\u00a0<\/span><\/p>\n

For medico-legal stakeholders, transparency may also influence complaints, claims and early resolution. Patients and families increasingly expect clear explanations,\u00a0timely\u00a0disclosure, accessible\u00a0records\u00a0and evidence that learning has occurred. Where data shows variation or delay, providers will need to\u00a0demonstrate\u00a0what was known, what was done and how risk was managed.<\/span>\u00a0<\/span><\/p>\n

The practical implication is that documentation,\u00a0governance\u00a0and communication become even more important. In a more transparent system, defensible care depends not only on clinical decision-making, but also on the ability to\u00a0evidence\u00a0that decisions were reasonable,\u00a0timely, explained and reviewed.<\/span>\u00a0<\/span><\/p>\n

What this means now<\/h3>\n

The March Board papers do not provide a clinical negligence bill. They do not quantify claims costs. They do not\u00a0establish\u00a0liability. But they do\u00a0identify\u00a0a set of patient safety signals that should matter to every provider board, clinical governance\u00a0team\u00a0and medico-legal stakeholder.<\/span>\u00a0<\/span><\/p>\n

The main signals are clear. Speaking-up confidence has weakened. Mortality variation requires review. CQC safe ratings show significant room for improvement. Diagnostic,\u00a0cancer\u00a0and community delays\u00a0remain\u00a0material. Infection indicators are mixed. Maternity and neonatal safety show progress but continuing risk. Mental health safety has improved in some\u00a0areas\u00a0but patient experience\u00a0remains\u00a0challenged. Transparency is increasing.<\/span>\u00a0<\/span><\/p>\n

For patients, these signals affect access, confidence,\u00a0safety\u00a0and experience. For healthcare workers, they affect escalation, decision-making, moral\u00a0pressure\u00a0and the ability to practise safely. For provider leaders, they reinforce the need for earlier assurance, stronger board oversight, better documentation, clearer\u00a0communication\u00a0and a culture where concerns are acted on.<\/span>\u00a0<\/span><\/p>\n

The\u00a0important point\u00a0is that risk should be understood before it becomes a claim. The strongest medico-legal systems are not only reactive. They support early review, clinical\u00a0learning,\u00a0accurate\u00a0causation analysis, robust expert\u00a0opinion\u00a0and fair resolution where harm has occurred.<\/span>\u00a0<\/span><\/p>\n

The central system implication is this:\u00a0<\/span>patient safety and medico-legal risk in 2026 will be shaped less by any single headline metric and more by the NHS\u2019s ability to\u00a0identify\u00a0delay,\u00a0variation\u00a0and cultural risk early enough to act.<\/span><\/b>\u00a0<\/span><\/p>\n

References<\/h3>\n
    \n
  • NHS England,\u00a0<\/span>Integrated Performance Report<\/span><\/i>, March 2026.\u00a0<\/span><\/li>\n
  • NHS England,\u00a0<\/span>Board Committee updates \u2013 NHS England People Committee<\/span><\/i>, March 2026.\u00a0<\/span><\/li>\n
  • NHS England,\u00a0<\/span>Minutes of a public meeting of the NHS England Board held on Thursday 5 February 2026<\/span><\/i>, published March 2026.\u00a0<\/span><\/li>\n
  • NHS England,\u00a0<\/span>Board Committee updates \u2013 NHS England Strategy Committee<\/span><\/i>, March 2026.\u00a0<\/span><\/li>\n
  • NHS England,\u00a0<\/span>Meeting of the Board of NHS England \u2013 agenda<\/span><\/i>, 26 March 2026.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    The March 2026 NHS England Board papers show a patient safety picture that is improving in some\u00a0areas, but\u00a0still carrying significant risk.\u00a0 There are positive signals. Stillbirth and neonatal death rates have reduced. Crisis care face-to-face contact within 24 hours has improved. Restrictive intervention use in mental health has reduced year on year. Some healthcare-associated infection…<\/p>\n","protected":false},"author":26,"featured_media":63866,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","footnotes":""},"categories":[459,25,456],"tags":[],"class_list":["post-63863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-governance","category-healthcare-leadership","category-medico-legal"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/comments?post=63863"}],"version-history":[{"count":1,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63863\/revisions"}],"predecessor-version":[{"id":63867,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63863\/revisions\/63867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media\/63866"}],"wp:attachment":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media?parent=63863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/categories?post=63863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/tags?post=63863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}